From Lab to Clinic: Kinvard Bio Accelerates Antibiotic Pipeline with CARB-X Support
Kinvard Bio Inc., a biotechnology firm at the forefront of developing a new generation of broad-spectrum antibiotics, has announced the receipt of US $2.7 million in follow-on non-dilutive funding from CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator). This global non-profit initiative…